Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UCHL1 | P09936 | 1/20 | 0.43 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 9/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12934486 | 0.92 | UCHL1 (0.43) | UCHL1P2RX3PDE4BMCL1NR1H2 | |
| SCHEMBL8253556 | 0.90 | UCHL1 (0.45) | UCHL1P2RX3MCL1NR1H2NR1H3 | |
| SCHEMBL8213225 | 0.89 | UCHL1 (0.45) | UCHL1P2RX3MCL1MEN1KMT2A | |
| SCHEMBL4406698 | 0.87 | UCHL1 (0.49) | UCHL1P2RX3MCL1SMN1; SMN2ACACB | |
| SCHEMBL8246971 | 0.87 | UCHL1 (0.49) | UCHL1P2RX3MCL1SMN1; SMN2ACACB | |
| SCHEMBL12963581 | 0.87 | MEN1 (0.39) | MEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL8275065 | 0.86 | KDM4E (0.48) | UCHL1P2RX3MCL1MEN1KMT2A | |
| SCHEMBL13123350 | 0.86 | KDM4E (0.48) | UCHL1P2RX3MCL1MEN1KMT2A | |
| SCHEMBL8248157 | 0.86 | UCHL1 (0.47) | UCHL1P2RX3MCL1NR1H2NR1H3 | |
| SCHEMBL2897360 | 0.85 | SMN1; SMN2 (0.40) | MEN1KMT2AKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8377874-B2 | HCV NS3 protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-02-19 | — | — | US | disclosed |
| US-8377874-B2 | HCV NS3 protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-02-19 | — | — | US | disclosed |
| US-20100286185-A1 | HCV NS3 Protease Inhibitors | MERCK SHARP & DOHME LLC | 2010-11-11 | — | — | US | disclosed |
| WO-2008057208-A2 | HCV NS3 PROTEASE INHIBITORS | MERCK & CO., INC. (US) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286185-A1 | HCV NS3 Protease Inhibitors | HAVCR2, GTF3C3, CTSC | UCHL1 483/4885P2RX3 3516/4885PDE4B 3619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.